Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted seven new employees restricted stock units to acquire 94,750 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.

About Adamas Pharmaceuticals, Inc.

At Adamas our vision is clear – to deliver innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. We are a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. For more information, please visit www.adamaspharma.com.

Media: Sarah Mathieson Vice President, Corporate Communications 510-450-3528 smathieson@adamaspharma.com

Investors: Peter Vozzo Westwicke Partners 443-213-0505 peter.vozzo@westwicke.com

Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Adamas Pharmaceuticals Charts.
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Adamas Pharmaceuticals Charts.